Valuation dashboard for Ascendis Pharma A/S (ASND) with P/E 18.46, P/B 10.01, EV/EBITDA 182.6 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.
Analysis Summary
Ascendis Pharma A/S reported revenue of 691.7M EUR in the most recent fiscal year, growing at a 5-year CAGR of 150.9%.
Trailing-twelve-month margins: gross margin 90.2%, operating margin 10.4%, net margin 71.7%.
At $250.17 (closing price, November 3, 2026), ASND trades at a P/E of 18.46 and an ROE of 190.44%. Market capitalisation stands at $16.5B, placing it among large-cap names.
Balance sheet quality for ASND: debt-to-equity ratio of 0.31, current ratio of 2.99 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 18.46 |
| Price / Book | 10.01 |
| EV / EBITDA | 182.6 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | $16.5B | 18.46 | 10.01 | 190.4% |
| INSM | Insmed Incorporated | $22.9B | 31.46 | -82.7% | |
| UTHR | United Therapeutics Corporation | $25.8B | 21.54 | 4.00 | 20.2% |
| NBIX | Neurocrine Biosciences, Inc. | $16.8B | 24.46 | 4.32 | 19.7% |
| BMRN | BioMarin Pharmaceutical Inc. | $10.8B | 1.72 | -0.3% | |
| CORT | Corcept Therapeutics Incorporated | $8.9B | 64.51 | 10.48 | 22.6% |
| MBX | MBX Biosciences, Inc. Common Stock | $2.6B | 6.41 | -26.0% | |
| SEPN | Septerna Inc | $2.0B | 5.09 | -6.3% |
Price
| Price | $250.17 (closing price, November 3, 2026) |
| Market Cap | $16.5B |
| Exchange | NASDAQ |
| Country | DK |
Profitability
| Return on Equity | 190.44% |
| Return on Invested Capital | 5.80% |
| Return on Assets | 33.08% |
| Gross Margin | 90.19% |
| Operating Margin | 10.38% |
| Net Margin | 71.69% |
Related companies: INSM · UTHR · NBIX · BMRN · CORT · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of ASND: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks